🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Alivus Life Sciences Limited ALIVUS NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.alivus.com
Company Profile ↓
₹1,165.30
+14.61% 1Y
Mkt Cap₹14,302.47 Cr
P/E25.39
P/B4.28
Div. Yield0.43%
52W High₹1,165.30
52W Low₹860.05
Book Value₹271.49
EPS (TTM)₹45.90

Company Overview

Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 16.9%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 21.8%.

Reasonable Valuation

Trades at a P/E of 25.4, below the sector median of 40.0.

Healthy Margins

Maintains a net profit margin of 22.1%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹2,551.83 Cr (+6.9% YoY); net profit ₹564.48 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +6.9%, earnings +16.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 7.6%, profit CAGR 6.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:7.61%
1 Year:6.91%

Compounded Profit Growth

5 Years:6.53%
1 Year:16.24%

Stock Price Performance

1 Year:+14.61%
6 Months:+29.01%
3 Months:+8.78%
1 Month:+10.85%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
₹860.05 ₹1,165.30
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)66.15 · Neutral
Price Performance
1M+10.85%
3M+8.78%
6M+29.01%
1Y+14.61%
Valuation vs Sector

P/E of 25.39 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 21.8%.
  • Excellent profit margin of 22.1%.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
25.39
Industry PE
39.97
Forward P/E
20.09
PEG Ratio
-
Book Value
₹271.49
Price to Book
4.28
P/S
5.58
EV/EBITDA
16.98
Dividend Yield
0.43%

Growth (CAGR)

Revenue 5Y
7.61%
Profit 5Y
6.53%
Revenue (YoY)
6.91%
Earnings (YoY)
16.24%

Profitability & Returns

ROCE
21.78%
ROE
16.94%
ROA
14.17%
Profit Margin
22.12%
Op Margin
28.29%
Gross Margin
58.20%
EPS (Latest Qtr)
₹13.22
EPS (TTM)
₹45.90

Balance Sheet & Liquidity

Debt/Equity
1.70
Quick Ratio
3.85
Current Ratio
5.21
Debt
₹56.77 Cr
Total Assets
₹3,982.90 Cr
Current Assets
₹2,649.36 Cr
Working Capital
₹2,141.32 Cr

Ownership

Promoter Holding
76.10%
Chg in Prom Hold
1.23%
FII / Inst Holding
8.79%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
₹14,302.47 Cr
Total Revenue (TTM)
₹2,551.83 Cr
EBITDA
₹832.04 Cr
Free Cash Flow
₹258.36 Cr
Operating Cash Flow
₹565.41 Cr
Shares Outstanding
₹12.27 Cr
Gross Margin
58.20%
Payout Ratio
10.89%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ALIVUS Alivus Life Sciences Limited NSEPHARMA 1,165.30 25.39 ₹14,302.47 Cr 0.43% 21.78% 16.94% 7.61% 6.53%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Dec 2025Mar 2026
Revenue 641.84 Cr649.54 Cr601.85 Cr672.89 Cr689.12 Cr
Cost of Revenue 285.27 Cr282.60 Cr270.38 Cr276.42 Cr270.85 Cr
Gross Profit 356.57 Cr366.95 Cr331.46 Cr396.47 Cr418.27 Cr
Operating Expenses 181.42 Cr184.49 Cr176.21 Cr184.86 Cr223.94 Cr
Operating Income 175.15 Cr182.46 Cr155.25 Cr211.62 Cr194.33 Cr
EBITDA 200.76 Cr208.52 Cr181.30 Cr219.54 Cr237.31 Cr
Interest Expense 45.80 L1.26 Cr1.25 Cr1.49 Cr1.31 Cr
Pretax Income 185.15 Cr191.29 Cr162.98 Cr198.39 Cr215.80 Cr
Tax Provision 48.19 Cr49.42 Cr41.45 Cr48.13 Cr53.14 Cr
Net Income 136.96 Cr141.87 Cr121.53 Cr150.26 Cr162.66 Cr
Diluted EPS 11.1411.559.8812.2213.22

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 886.00 Cr1,537.00 Cr1,885.00 Cr-2,047.84 Cr2,184.77 Cr2,386.88 Cr2,551.83 Cr
Cost of Revenue ----1,031.35 Cr1,020.70 Cr1,080.85 Cr1,066.57 Cr
Gross Profit ----1,016.50 Cr1,164.07 Cr1,306.03 Cr1,485.26 Cr
Operating Expenses 639.00 Cr1,065.00 Cr1,294.00 Cr-415.74 Cr541.93 Cr684.06 Cr763.34 Cr
Operating Income 229.00 Cr443.00 Cr558.00 Cr-600.76 Cr622.13 Cr621.98 Cr721.93 Cr
EBITDA 248.00 Cr472.00 Cr591.00 Cr-671.25 Cr686.29 Cr717.15 Cr832.04 Cr
Interest Expense 1.00 Cr34.00 Cr88.00 Cr-54.70 L1.55 Cr2.41 Cr5.37 Cr
Pretax Income 228.00 Cr421.00 Cr471.00 Cr-628.61 Cr631.29 Cr654.13 Cr751.31 Cr
Tax Provision 31.92 Cr109.46 Cr117.75 Cr-161.65 Cr160.40 Cr168.50 Cr186.83 Cr
Net Income 196.00 Cr313.00 Cr352.00 Cr-466.96 Cr470.89 Cr485.63 Cr564.48 Cr
Diluted EPS 997.861,597.37358.74-38.1138.3839.5245.90

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -2,702.15 Cr2,850.41 Cr3,411.45 Cr3,982.90 Cr
Current Assets -1,850.34 Cr1,916.00 Cr2,335.16 Cr2,649.36 Cr
Cash & Equivalents -283.82 Cr301.41 Cr71.06 Cr1.98 Cr
Inventory -604.17 Cr666.59 Cr673.95 Cr691.93 Cr
Receivables -806.77 Cr765.43 Cr969.74 Cr1,072.96 Cr
Total Liabilities -563.94 Cr518.09 Cr594.08 Cr650.76 Cr
Current Liabilities -496.54 Cr438.77 Cr470.16 Cr508.04 Cr
Long Term Debt -----
Total Debt -19.36 Cr17.15 Cr56.61 Cr56.77 Cr
Total Equity -2,138.21 Cr2,332.32 Cr2,817.37 Cr3,332.13 Cr
Shares Outstanding -12.25 Cr12.25 Cr12.25 Cr12.27 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -306.01 Cr413.51 Cr391.52 Cr565.41 Cr
Investing Cash Flow --146.75 Cr-116.48 Cr-615.64 Cr-570.15 Cr
Financing Cash Flow --387.59 Cr-279.44 Cr-6.23 Cr-64.34 Cr
Capital Expenditure --162.80 Cr-128.97 Cr-166.19 Cr-307.06 Cr
Free Cash Flow -143.21 Cr284.55 Cr225.34 Cr258.36 Cr
Net Change in Cash --228.33 Cr17.59 Cr-230.35 Cr-69.08 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ----49.6%53.3%54.7%58.2%
Operating Margin % 25.8%28.8%29.6%-29.3%28.5%26.1%28.3%
Net Margin % 22.1%20.4%18.7%-22.8%21.6%20.3%22.1%
ROE % ----21.8%20.2%17.2%16.9%
ROCE % ----27.2%25.8%21.1%20.8%

Shareholding Pattern

Insiders
76.10%
Institutions
8.79%
Public Float
36.76%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ALIVUS

Yahoo Finance Fri, 15 May 2026

Alivus Life Sciences Ltd (BOM:543322) Q4 2026 Earnings Call Highlights: Record EBITDA Margins ...

Alivus Life Sciences Ltd (BOM:543322) reports historic EBITDA margins and robust portfolio expansion, while navigating external pressures and operational setbacks.

Yahoo Finance Sat, 24 Jan 2026

Alivus Life Sciences Ltd (BOM:543322) Q3 2026 Earnings Call Highlights: Record Revenue and ...

Alivus Life Sciences Ltd (BOM:543322) reports its highest-ever quarterly revenue and significant margin improvements, driven by new product launches and operational efficiencies.

Yahoo Finance Mon, 10 Nov 2025

Alivus Life Sciences Ltd (BOM:543322) Q2 2026 Earnings Call Highlights: Strong Revenue Growth ...

Alivus Life Sciences Ltd (BOM:543322) reports a robust 16% revenue growth and improved EBITDA margins, while addressing challenges in the GPL and CDMO segments.

ALIVUS — Frequently Asked Questions

What is the current share price of Alivus Life Sciences Limited (ALIVUS)?

As of 2026-07-15 09:52 IST, Alivus Life Sciences Limited (ALIVUS) trades at ₹1,165.30 on NSE. Its 52-week range is ₹860.05 to ₹1,165.30.

What is the market capitalisation of ALIVUS?

Alivus Life Sciences Limited (ALIVUS) has a market capitalisation of ₹14,302.47 Cr on NSE.

What is the P/E ratio of ALIVUS?

ALIVUS trades at a trailing price-to-earnings (P/E) ratio of 25.39. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 4.28.

Does ALIVUS pay a dividend?

Alivus Life Sciences Limited (ALIVUS) currently offers a dividend yield of 0.43%.

What is the return on equity (ROE) of ALIVUS?

ALIVUS has a return on equity (ROE) of 16.94%. Its return on capital employed (ROCE) is 21.78%.

Is ALIVUS a good stock to buy?

This page provides a data-driven analysis of Alivus Life Sciences Limited (ALIVUS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space